-
DNA changes in a gene that drives the growth of a form of lung cancer can make the cancer’s cells resistant to cancer drugs. The findings show that some classes of drugs won’t work, and certain types of so-called kinase inhibitors like erlotinib—may be the most effective at treating non-small cell lung cancers with those DNA changes. Some kinase inhibitors block a protein known as EGFR from directing cells to multiply.
Johns Hopkins Hospital (Oncology) - Tue, 24 January 2012
http://www.hopkinshospital.org
-
According to new research published in the British Journal of Cancer, eating too much processed meat may increase the risk of pancreatic cancer. The study found that for each 50 grams of processed meat eaten every day - equivalent to a sausage or two rashers of bacon - there was a 19 per cent rise in the risk of pancreatic cancer compared to those who ate no meat.
Karolinska Institutet (Oncology) - Tue, 24 January 2012
http://ki.se/ki/jsp/polopoly.jsp?d=130&l=en
-
A new study published in the Journal of Clinical Oncology shows that most patients who survive for at least five years after oesophageal cancer surgery recover an average quality of life. However, quality of life deteriorates significantly for one in six patients to a level that remains much lower than the average population in the five years after surgery. This suggests, say the researchers, that hospitals must be better at identifying this patient group.
Karolinska Institutet (Oncology) - Tue, 24 January 2012
http://ki.se/ki/jsp/polopoly.jsp?d=130&l=en
-
Adding oxaliplatin to a standard chemotherapy regimen boosts survival rates for patients with advanced colon cancer, according to a new study that bolsters previous research on the drug by looking at a broader group of patients.
Medline Plus (Oncology) - Tue, 24 January 2012
http://www.nlm.nih.gov/medlineplus
-
In the setting of CXR screening offered to a population-based cohort of smokers, screening participants who were diagnosed with LC had more frequently early-stage resectable disease and significantly enhanced long-term LC survival. These results translated into enhanced 10-year LC survival, independently related to CXR screening exposure, in the entire population-based cohort.
BioMed Central (Oncology) - Tue, 17 January 2012
http://www.biomedcentral.com
-
Human septins are a conserved family of GTPase proteins, encoded at thirteen loci scattered throughout the human genome. Of these, SEPT9 has been most widely implicated in diverse cancers of epithelial origin, including breast cancer, as well as leukemia. In this issue, Connolly et al. present compelling data that further supports a role for involvement of SEPT9 isoforms early in mammary tumorigenesis as well as intriguing evidence that suggests that different cellular localization patterns of SEPT9 isoforms may be a contributing factor in oncogenesis.
Breast Cancer Research (Oncology) - Tue, 10 January 2012
http://breast-cancer-research.com/
-
It is well known that oral bisphosphonates can provoke esophageal inflammation; so, researchers have wondered whether these inflammations can be the symptom of cancer onset. Some English researchers have then performed a case-control trial to verify the relation between oral bisphosphonates and gastrointestinal cancers in general: the U.K. General Practice Research database has been used to identify about 16,000 subjects with esophageal, gastric and colorectal cancers diagnosed between 1995 and 2005.
MedNews (Oncology) - Mon, 9 January 2012
http://mn.medsurfnews.com/
-
Just as people’s bodies and minds can become addicted to substances such as drugs, caffeine, alcohol, their cancers can become addicted to certain genes that ensure their continued growth and dominance. Researchers at Baylor College of Medicine and Harvard Medical School have developed ways to exploit the addictions of cancers to kill them without harming normal tissues. A report on their work appears online in the journal Science.
Baylor College of Medicine (Oncology) - Tue, 13 December 2011
http://www.bcm.edu
-
Researchers at Karolinska Institutet have demonstrated that a growth hormone, PDGF-BB, and the blood protein EPO are involved in the development of cancer tumours and that they combine to help the tumours proliferate in the body. These new preclinical findings offer new potential for inhibiting tumour growth and bypassing problems of resistance that exist with many drugs in current use. The results are published in the scientific journal Nature Medicine.
Karolinska Institutet (Oncology) - Tue, 6 December 2011
http://ki.se/ki/jsp/polopoly.jsp?d=130&l=en
-
Ten-year survival rates are high when patients with unfavorable localized prostate cancer are treated with external beam radiotherapy boosted with conformal high-dose-rate brachytherapy, a Spanish group reports.
Medscape (Oncology) - Tue, 6 December 2011
http://www.medscape.com